Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label Phase 1 Study of HGI-001 Injection in Transfusion-Dependent Beta-Thalassemia
TCTR20241029003Phase 1Not yet recruiting
- Sponsor
- Hemogen HongKong Alpha Technology, Ltd
- Start
- Jan 2025
- Modality
- Cell Therapies, Gene Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of LentiHBBT87Q in beta thalassemia, sponsored by Hemogen HongKong Alpha Technology, Ltd. Planned start Jan 2025; status: not yet recruiting.
02
Drugs
LentiHBBT87Q
03
Conditions
beta thalassemia
Beyond the preview
Go deeper on TCTR20241029003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20241029003.